Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Aurore Perrot | Researchclopedia

Back to researchers

Aurore Perrot

Institut universitaire du cancer de Toulouse Oncopole ORCID

439

Works

11,116

Citations

44

h-index

143

i10-index

Research Topics

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis

Affiliations

Centre National de la Recherche Scientifique2023–2024

Université Toulouse III - Paul Sabatier2020–2025

Inserm2018–2024

Université Fédérale de Toulouse Midi-Pyrénées2018–2025

Dokuz Eylül University2023–2023

Top Works

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon,Shaji Kumar,et al.

2019972 citations

Chronic Lymphocytic Leukemia Research

Cancer Treatment and Pharmacology

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau,Michel Attal,et al.

2019937 citations

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari,Dan T. Vogl,et al.

2019664 citations

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal,Paul G. Richardson,et al.

2019625 citations

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld,Meletios Α. Dimopoulos,et al.

2023469 citations

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson,Susanna Jacobus,et al.

2022443 citations

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot,Valérie Lauwers‐Cancès,et al.

2018412 citations

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Thierry Façon,Shaji Kumar,et al.

2021352 citations

Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Philippe Moreau,Michel Attal,et al.

2017313 citations